Lupin Strengthens US Portfolio With FDA Nod For Famotidine Injection

Ashik Bothra May 13, 2026 360 Views

Lupin has received US FDA approval for its Famotidine Injection, USP, expanding its injectable product portfolio in the United States. The approval enhances Lupin’s presence in the high-value generics market and supports its strategy to grow in complex formulations and hospital-focused therapies.